NCT05512819View on ClinicalTrials.gov

A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

401

Participants

Timeline

Start Date

September 16, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Pneumococcal Disease
Interventions
BIOLOGICAL

20-valent pneumococcal conjugate vaccine

20-valent pneumococcal conjugate vaccine

BIOLOGICAL

13-valent pneumococcal conjugate vaccine

13-valent pneumococcal conjugate vaccine

Trial Locations (11)

333

Chang Gung Medical Foundation-Linkou Branch, Taoyuan District

10002

National Taiwan University Hospital, Taipei

10449

Mackay Memorial Hospital, Taipei

30071

Hsinchu Mackay Memorial Hospital, Hsinchu

110002

Maulana Azad Medical College and Associated with Lok Nayak Hospital, New Delhi

305001

Jawahar Lal Nehru Medical College, Ajmer

395002

Nirmal Hospital Pvt Ltd., Surat

407219

Taichung Veterans General Hospital, Taichung

411043

Bharati Vidyapeeth {Deemed to be University) Medical College Hospital & Research Centre, Pune

560060

BGS Global Institute of Medical Sciences (BGSGIMS), Bangalore

700017

Institute of Child Health, Kolkata

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05512819 - A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan | Biotech Hunter | Biotech Hunter